Member Info for Lionel1

This is published on 24th June 2025 , Genedrive working on new assay ??

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5293260

Https://ep.bmj.com/content/edpract/early/2025/06/26/archdischild-2024-328158.full.pdf

Roger , Why do you care ?? You are not even invested here , come on .. you seems to be clever enough but still acting dum**

Thanks Busicat.

Finally they are promoting the right way .

Russ Shaw.

https://www.thebusinessdesk.com/northwest/news/2154633-manchester-announces-major-investment-drive-to-accelerate-life-sciences-growth

Lol Nissan :-) , no rockets for you today ..come back in 3 years , somebody needs to step and fire this BOD.

Https://www.linkedin.com/posts/emqn_find-out-more-activity-7344273287318790145-m7To?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

I think NHS itself behind these tests and somehow they don’t let it fail , The adoption is slow but once it’s implemented good days for GDR. Come back in 2027 , my exit sp is 30 P and it’s fairly possible by end of 2027 or early 2028 .

Things to look out for.

1. FDA application for MT RNR1 testing in early 2026

2. FDA approval late 2026

3. UK/EU sales for cyp2c19

I personally believe there will be another fund raise towards the end of this year or before that , Market knows that they are getting closer to sales so they will get the amount they are looking for go for . Good luck all

Very Good info .

https://www.diagnosticsworldnews.com/news/2025/06/11/pharmacogenomic-testing-shows-value-in-improving-prescribing-precision?

From Reactive to Preemptive Testing

The research team is exploring two advanced approaches to overcome the current seven-day turnaround time for results. One involves preemptive testing where genetic information would be collected and stored in patient records before medications are needed. The other focuses on point-of-care testing strategies, including rapid testing in neonatal intensive care units to prevent antibiotic-induced deafness in babies.

Looking ahead, the NHS plans to evaluate whether the pharmacogenomics program decreases overall healthcare utilization in real-world practice, providing crucial evidence for the economic value of precision medicine approaches.

https://www.bio-itworld.com/news/2025/06/26/uk-study-demonstrates-real-world-value-of-genetic-testing-for-drug-prescribing#

For god sake EC please stop it , are you on drugs , meds, steroids ???

Https://www.linkedin.com/posts/north-west-genomic-medicine-service-alliance_new-rapid-genetic-test-will-help-to-treat-activity-7340712731521499136-lx42?utm_medium=ios_app&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY&utm_source=social_share_send&utm_campaign=copy_link

Https://www.linkedin.com/posts/faculty-of-biology-medicine-health_a-40-minute-test-could-reduce-the-risk-of-activity-7338082525937852416-Ijik?utm_medium=ios_app&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY&utm_source=social_share_video_v2&utm_campaign=copy_link

Https://www.diagnosticsworldnews.com/news/2025/06/11/pharmacogenomic-testing-shows-value-in-improving-prescribing-precision

Https://www.script-talk.com/groups

Summary of the PROGRESS Trial: Bringing Pharmacogenomics into English Primary Care

Overview:

The PROGRESS trial, launched in June 2023 and funded by NHS England, aims to integrate pharmacogenomics into primary care prescribing. Led by Manchester University NHS Foundation Trust and the North West Genomic Medicine Service Alliance, the project seeks to develop a scalable NHS-wide service.

⸻

Phase I Highlights:

• Conducted in 5 GP networks in NW England, with 250+ patients.

• Genetic testing for those starting statins, SSRIs, TCAs, or PPIs.

• 28% received actionable genetic results prompting prescription changes.

• Included patients aged 18–92; used remote e-consent and streamlined logistics.

⸻

Phase II Developments (Early 2025):

• Expanded to ~20 GP practices across England.

• 673+ samples processed; 93% had actionable variants; 10% flagged for urgent drug changes.

• 35% of ~376 prescriptions were adjusted; 80% adherence to genomic advice.

⸻

Tech Innovation – ProgressRx:

• Real-time prescribing alerts integrated into EMIS and SystmOne.

• Links to the NHS Unified Genomic Record.

• Reduces prescriber burden and supports lifelong use of genomic data.

⸻

Pharmacists’ Role:

• Identify eligible patients during reviews.

• Interpret results and guide prescription changes.

• Collaborate with GPs and patients.

• Prepare for a new competency framework (launching Nov 2025).

⸻

Clinical & Economic Significance:

• 95% of participants had relevant genetic variants.

• 25–35% had prescriptions modified accordingly.

• Potential for cost savings via fewer adverse drug events and better prescribing.

⸻

Next Steps:

• NHS commissioning decisions expected by late 2025/early 2026.

• Emphasis on national scaling, system integration, and workforce training.

⸻

Conclusion:

PROGRESS is a landmark trial for embedding genomics into NHS care. With strong pharmacist involvement and growing clinician trust, it marks a shift toward personalized medicine. Pharmacists are encouraged to get trained, embrace genomic tools, and lead this healthcare transformation.

Cardiovascular disease (CVD) in Greater Manchester (GM), is estimated to cost £2.5 billion a year.

A new independent report by Frontier Economics outlines the social and economic cost of CVD on the NHS, social care and broader society.

This includes reduced quality of life, the strain on informal caregivers, and economic losses from higher sickness rates and decreased employment.

This is an average of £13,700 per patient, with costs increasing for people with multiple conditions 

CVD claims nearly 5,500 lives a year in GM which has highest regional death rate from CVD in England. 

HInM is taking action to address this health issue by focusing on prevention, early detection, and improving care.

https://www.linkedin.com/posts/health-innovation-manchester_greater-manchester-counts-the-cost-of-cvd-activity-7336326762999545856-NIgA?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

Https://www.linkedin.com/posts/johnhmcdermott_pharmacogenomics-in-the-uk-national-health-activity-7336077622474403841-EcZZ?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

Thx busicat .

More context , excellent article about the possibilities and beyond .

Pharmacogenetics enters the GP's office

One might think that the implementation of pharmacogenetics in clinical practice should be reserved for a few specialized centers with expert personnel, excluding for example general practitioners (GPs). In fact, a GP cannot wait for months for a result before prescribing a therapy and cannot even become an expert in pharmacogenetics to be able to interpret a test performed on a patient.

In fact, this approach can also become part of the daily work of GPs. The results of the PROGRESS study, presented at the congress, suggest that the implementation of pharmacogenomics in GP surgeries is not only possible, but is also highly appreciated by doctors and patients. "By talking to GPs, we understood that the implementation program had to have two main characteristics: it had to be fast and simple," explained John McDermott , from the University of Manchester, presenting the data during a session dedicated to the topic.

The PROGRESS programme was built on this premise, involving patients from 20 sites across England and focusing in particular on the prescribing of common medicines – statins, opioids, antidepressants and proton pump inhibitors.

The patient goes to their GP and, if they are considering prescribing one of the drugs being studied, the doctor suggests the possibility of taking the test and waiting for the results before starting treatment. If the patient accepts, they are given a kit to take home containing all the instructions for filling out the informed consent form online and collecting a saliva sample. The sample is then sent to the laboratory for analysis, using any post box in the United Kingdom. "Most doctors and patients said they were willing to wait for the result - also because the program envisaged a wait of no more than 10 days," McDermott told Univadis Italia . The genomic data obtained are not forwarded as is to the GP, who instead receives only specific "alerts", inserted into the electronic medical record.

https://www.univadis.it/viewarticle/eshg-2025-futuro-prossimo-test-genetico-prima-prescrivere-2025a1000djk?uuid=f6aaf61a-81b1-4f31-b1c3-337d1b25164c

@Gloria , The true value and return for the investment is 2027 for me. Hope someone don’t takeover this for peanuts before 2027. I am expecting 4£ for every 1£ I have invested here, that’s minimum .

Https://www.linkedin.com/posts/genedrive-plc_strokeawarenessmonth-precisionmedicine-strokeprevention-activity-7332680664527290368-fCHx?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

@Stickpickfree , can you name few hot ones ??